The Cost Effectiveness of Levodopa-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson’s Disease in England-Reference-Cited by-同舟云学术

The Cost Effectiveness of Levodopa-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson’s Disease in England

Published:2022-03-21 Issue:5 Volume:40 Page:559-574
ISSN:1170-7690
Container-title:PharmacoEconomics
language:en
Short-container-title:PharmacoEconomics

Author:

Chaudhuri K. Ray,Pickard A. Simon,Alobaidi Ali,Jalundhwala Yash J.,Kandukuri Prasanna L.,Bao Yanjun,Sus Julia,Jones Glynn,Ridley Christian,Oddsdottir Julia,Najle-Rahim Seyavash,Madin-Warburton Matthew,Xu Weiwei,Schrag Anette

Funder

abbvie inc

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health,Health Policy,Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s40273-022-01132-y.pdf

Reference68 articles.

1. Michael J Fox Foundation for Parkinson’s Research. Parkinson's disease symptoms. https://www.michaeljfox.org/understanding-parkinsons/living-with-pd/topic.php?symptoms&navid=symptoms. Accessed 3 Feb 2022.

2. Martinez-Martin P, Rodrigurez-Blazquez C, Kurtis M, et al. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson’s disease. Mov Disord. 2011;26(3):399–406.

3. Pfeiffer RF. Non-motor symptoms in Parkinson’s disease. Parkinsonism Relat Disord. 2016;22:S119–22.

4. Pringsheim T, Jette N, Frolkis A, et al. The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2014;29(13):1583–90.

5. de Lau LM, Breteler MM. Epidemiology of Parkinson’s disease. Lancet Neurol. 2006;5(6):525–35.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Subcutaneous Levodopa: A New Engine for the Vintage Molecule;Neurology and Therapy;2024-06-14

2. Levodopa-based device-aided therapies for the treatment of advanced Parkinson’s disease: a social return on investment analysis;Frontiers in Public Health;2024-06-06

3. Levodopa infusion therapies for Parkinson disease;Current Opinion in Neurology;2024-05-23

4. Can Continuous Levodopa Delivery Be Achieved in the Absence of Intrajejunal Levodopa Infusion? Implications for India and Underserved Countries;Movement Disorders Clinical Practice;2023-11-28

5. Cost‐Effectiveness of Carbidopa‐Levodopa Enteral Suspension for Advanced Parkinson's Disease in the United States;Movement Disorders;2023-10-25